Skip to main content
. Author manuscript; available in PMC: 2012 Oct 28.
Published in final edited form as: Transfusion. 2010 Jan;50(1):267–269. doi: 10.1111/j.1537-2995.2009.02446.x

Table 2.

Serologic results of RhD and RhCE variants with amino acid substitutions at positions 114 and 122

Amino acid position Protein Trivial name† Amino acid substitution Titer with polyclonal antisera*
Number of samples
anti-JAL Pas anti-JAHK
P4.53A P4.53B P4.53C
114 RhCE CeMA R114W 512 0 0 0 1
Rhce(R114Q) R114Q 16 0 0 0 1
RhD Weak D type 17 R114W 0 0 0 0 1
Weak D type 25 R114Q 0 0 0 0 3
Weak D type 47 R114G 0 0 0 0 1
122 RhCE Ce(S122L) S122L 0 8 32 32 1
ceSL S122L 0 0 64 16 – 64 7
Ce(S122P) S122P 0 0 0 0 2
RhD Weak D type 54 S122L 0 0 0 0 1
110 RhD DVII L110P 0 0 0 0 1
*

Anti-JAL (Pas) was kindly provided by Hein Hustinx.2 The anti-JAHK antisera P4.53A,3 P4.53B and P4.53C7 were reported previously. Isoagglutinins and the known anti-E antibody in P4.53C were absorbed when needed; a titer of at least 8 was confirmed in all sera after absorption. Hemagglutination was performed in gel matrix technique (Liss-Coombs Scangel; Bio-Rad, Munich, Germany).

†

Initial deposition of the nucleotide sequences for JAL+ RHCe(R114W)1,2 and RHce(R114Q)2 variants under GenBank accession numbers AJ548431 and AJ548432. The ceSL samples were identical with the 7 previously reported RBC4 including one sample with the additional W16C substitution.